DRNA Projected Dividend Yield
Dicerna Pharmaceuticals Inc ( NASDAQ : DRNA )Dicerna Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to utilize ribonucleic acid interference to silence selectively genes that cause or contribute to disease. Nedosiran is Co.'s investigational product candidate for the treatment of primary hyperoxaluria (PH) type 1, PH type 2, and PH type 3. Co.'s GalXC product candidate, RG6346, is for the treatment of chronic hepatitis B virus (HBV) infection. Therapies for HBV include nucleoside analogs and pegylated interferon regimens. Co.'s another GalXC product candidate, belcesiran, is for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. 20 YEAR PERFORMANCE RESULTS |
DRNA Dividend History Detail DRNA Dividend News DRNA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |